SEPTIN9 and colorectal carcinoma: Furthermore, the promoter hypermethylation of septin 9 (SEPT9) in cfDNA has been confirmed as a potent biomarker in CRC, and the Epi proColon 2.0 kit for cell-free circulating methylated SEPT9 detection approval by the FDA as the first blood-based CRC screening test [81–83].